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Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81A56increased in severity and 13% decreased in severity over 10 years (Fig-1).
Offspring showed a signiﬁcantly higher increase in the mean score
compared to the controls at the medial tibial and femoral sites in par-
ticipants with a cartilage defect at baseline (Fig-2A). Offspring also
showed a signiﬁcantly higher number of incident cartilage defects at
the medial femoral site only in the participants without a defect at
baseline (Fig-2B).
Presence of tibiofemoral cartilage defects was independently associated
with higher odds of presence of effusion (Odd ratio (95%CI) ¼ 2.19 (1.07,
4.47)) at baseline. Presence and severity of JSN, osteophytes and BMLs
predicted change in total knee cartilage defects in unadjusted analysis,
however these associations only persisted for presence (b ¼ þ0.83
(þ0.32, þ1.60)) and severity (b (per grade) ¼ þ0.86 (þ0.02, þ1.70)) of
JSN and severity of BMLs (b (per unit area) ¼ þ0.64 (þ0.10, þ1.20)).
Change in total knee cartilage defects was associated with change in
BMI, pain and BMLs in the unadjusted analysis but these associations
persisted only for BMI (b ¼ þ0.13 (þ0.03, þ0.25)) in the fully adjusted
model. Change in cartilage defects also independently correlated with
change in JSN (r ¼ 0.16, p ¼ 0.04) but not osteophytes. Furthermore,
change in total knee cartilage defects was independently associated
with absolute (b¼ -123.87 (-193.24, -54.50)) and percentage per annum
(b ¼ -0.08 (-0.11, -0.04)) cartilage volume loss (using mixed model
analysis).
Conclusions: Data from this midlife cohort suggests that cartilage
defects are on the OA causal pathway both for symptoms and structure.
Unlike meniscal pathology, cartilage defects have the capacity to heal
over time thus may be amenable to intervention.
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Purpose: Total joint replacement surgery (TJR) is themost common and
costly procedure in the Medicare budget and TJR use is rapidly
expanding among adults under 65 years of age making TJR outcomes an
important public health issue. In September of 2012, the Center for
Medicare and Medicaid Services (CMS) issued preliminary hospital-
speciﬁc reports of ‘risk-adjusted’ 30 day readmission rates after TJR and
in 2013, CMS publicly reported hospital-speciﬁc TJR readmission rates.
The release of publicly reported TJR outcomes illustrates the importance
of accurate comparisons of post-TJR outcomes across hospitals and
surgeons. However, the CMS risk-adjustment models only apply to
patients over 65 years of age, are based solely on administrative billing
data and ICD-9 co-morbidity codes, and lack clinically reﬁnedmeasures.
We evaluated whether the addition of key pre-operative clinical risk
factors would improve the 30 day post-TJR readmission risk-adjustment
model.
Methods:Wemerged CMS patient-level data for those over 65 years of
age enrolled in the ﬁrst 18 months (June 2011-November 2012) in a
national cohort study (FORCE-TJR) of primary TKR and THR patients
from more than 130 surgeons in 22 states. CMS data include date and
ICD-9 codes for co-existing medical conditions up to 12 months pre-TJR
and readmissions within 30 days after TJR to an acute care hospital.
Additional clinical data from the FORCE-TJR cohort include BMI, medical
and musculoskeletal comorbidities, and pre-op patient-reported pain
and function (HOOS/KOOS; SF36).
Results: Five percent of 2560 patients across 31 sites were readmitted.
Readmission rates were greater among men and patients with the fol-
lowing administrative risk factors: older age, history of infection, COPD,
diabetes, disorders of ﬂuid/electrolytes, rheumatoid arthritis, and renal,
hematologic, and vascular conditions (all p>0.01). In addition, read-
mitted patients had lower pre-TJR function scores, a greater number of
knee/hip joints with moderate-to-severe pain, and greater Charlson
index (all p<0.01). In logistic multivariable models, the CMSmodel with
the addition of clinical measures (number of painful joints and Charl-
son) outperformed the CMS core model based only on ICD codes
[C¼0.65 (ICD/CMS) vs 0.76 (ICD þ Clinical model)].
Conclusions: The addition of patient-reported function and the clinical
severity of musculoskeletal and medical conditions co-existing at time
of surgery improved the 30 day readmission prediction model for TJR.
Public reporting based on risk models that do not address the completecomorbid proﬁle, including musculoskeletal conditions, may dis-
advantage hospitals and surgeons treating patients with the most
advanced disease. Further research should validate the enhanced risk
models in both older (Medicare) and younger TJR patients.
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Purpose: Dysregulated chondrocyte activation and differentiation in
articular cartilage is an important mechanism in Osteoarthritis (OA)
pathogenesis. Twist-related protein1 (TWIST1) is known as class A basic
helix-loop-helix protein 38 (bHLHa38), and involved in the negative
regulation of cellular determination and in the differentiation of several
lineages including myogenesis and osteogenesis. TWIST1 is also known
as a factor contributing to dedifferentiation and chondrogenesis. We
also found out TWIST1 was upregulated in human OA knee cartilage
tissue compared with normal knee through next-generation sequenc-
ing. In this study we revealed correlative relationship between TWIST1
and chondrogenesis-related genes (collagen type II alpha (COL2A1),
Sox 9).
Methods: Cartilage tissues and chondrocytes were obtained at autopsy
from normal knee joints (n¼7) and from OA joints (n¼8) at knee
arthroplasty. The expression level of TWIST1 in cartilage tissues were
determined by qRT-PCR. TWIST1 protein expression in cartilage tissue
was analyzed by immunohistochemistry in human and mouse OA
model. Human normal cartilage derived chondrocytes, TC28 (immor-
talized human chondrocytes) and SW1353 (human chondrosarcoma)
cells were used to study regulation of chondrogenesis-related genes by
TWIST1. TWIST1 was knocked down with small interfering RNA
(siRNA), and over expressed by pCMV6-Entry C-terminal Myc tagged
TWIST1 ORF vector. To further investigate the linkage between TWIST1,
COL2A1 and SOX9, we constructed luciferase reporters containing SOX9
3’ UTR, COL2A1 promoter and COL2A1 enhancer segments.
Results: TWIST1 expression was signiﬁcantly increased in human OA
knee cartilages compared to normal knee cartilages (5-6-fold up-reg-
ulation). Immunohistochemistry analysis showed only few Twist pos-
itive cells in normal human andmouse cartilage and increased numbers
of Twist1 positive cells in OA-affected tissues. Following TWIST1 siRNA
treatment of chondrocytes, qRT-PCR results showed SOX9, COL2A1 and
aggrecan gene expressions were up-regulated, and cartilage-degrading
enzymes (MMP-13, ADAMTS4) were down-regulated. In contrast, over
expression of TWIST1 suppressed COL2A1 gene expression, but not
SOX9. Luciferase activities of SOX9 3’UTR and COL2A1 promoter-luci-
ferase reporter were reduced after TWIST1 transfection. TWIST1 also
reduced COL2A1 enhancer-luciferase reporter activity, but there is no
TWIST1 binding site in COL2A1 enhancer. This data shows that TWIST1
might affect COL2A1 enhancer indirectly through SOX9 down-
regulation.
Conclusions: Overexpression of TWIST1 is a novel feature of OA
affected cartilage, and promotes catabolic reaction and abnormal
chondrocyte differentiation by interacting with COL2A1 promoter and
SOX9 3’UTR. Thus, dysregulated TWIST1 may be an important factor in
OA pathogenesis and a novel treatment target for OA.
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Purpose: Osteoarthritis (OA) is the most common degenerative joint
disease and knee OA often requires joint replacement to reduce pain
and restore joint mobility. The role of bone morphogenetic proteins
(BMP) in the pathogenesis of OA remains controversial despite many
years of study. BMP signaling is required for synovial joint formation
during development and is also involved in maintaining the normal
function of synovial joints after birth. Paradoxically, too much BMP
activity is also associated with synovial thickening and osteophyte
formation, hallmarks of OA progression. Mice lacking BMP2 in all limb
bud skeletal progenitors (BMP2-Prx1) develop OA of the elbows and
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bones that spontaneously fracture. The purpose of this study was to
deﬁne the role of BMP2 in the formation and maintenance of the knee
joint. In order to do this, we removed BMP2 speciﬁcally from synovial
joint cells using the Gdf5-cre transgene.
Methods:We generated BMP2 loss of function conditional mutant mice
using BMP2 ﬂoxed alleles. The Gdf5-cre transgene was used to specif-
ically delete BMP2 within synovial joints (BMP2-Gdf5 cKO) starting at
embryonic day 12.5 (E12.5). We performed histology, immunohis-
tochemistry (IHC), qRT-PCR, Xradia micro-CT, and Atomic Force
Microscopy based (AFM) nanoindentation to assess both molecular and
biomechanical changes in articular cartilage and meniscus during joint
formation, maturation and maintenance using hindlimbs isolated from
E17, 2 week, 8-10 week and 5 month old mice.
Results: Loss of BMP2 from synovial joint forming cells (BMP2-Gdf5
cKO) does not affect knee joint morphogenesis. At E17, the developing
meniscus, ligaments and articular surfaces of the tibia and femur all
appeared normal. At 2 weeks after birth, when joint structures are
maturing, the meniscus of the BMP2-Gdf5 cKO knees appeared devel-
opmentally delayed when compared to controls. Saf-O staining showed
reduced proteoglycan expression as well as decreased rounded chon-
drocyte like cells in BMP2-Gdf5 cKO meniscus. IHC analysis revealed
reduced collagen type 2 (Col2) and altered aggrecan distribution in
BMP2-Gdf5 cKO meniscus while picrosirius red staining showed a
disorganized pattern of collagen ﬁbers. This data was conﬁrmed using
qPCR analysis that showed a decrease in both Col2 and aggrecan
expression in 2 wk old menisci from BMP2-Gdf5 cKO mice compared to
controls and revealed that BMP target genes Lox (lysl oxidase) and
Runx2 were also down regulated. AFM nanoindentation testing of knee
joints of 2 wk old BMP2-Gdf5 and control mice revealed no signiﬁcant
differences in the nanomechanical properties of the articular cartilages.
However, menisci from BMP2-Gdf5 KO mice appeared to have weak-
ened mechanical function with signiﬁcantly lower indentation stiffness
when compared to controls. By 8-10 weeks of age, menisci from BMP2-
Gdf5 cKO knees appeared to be less ossiﬁed and continued to have
decreased expression of ECM components. In addition, knee joints of
the BMP2-Gdf5 cKO mice started to show signs of early OA as the
articular cartilage began to ﬁbrillate. By 5 months of age, Xradia micro-
CT analysis showed loss of BMP2 results in joint space narrowing,
ﬂattened tibial epiphyses, menisci that are smaller and signiﬁcantly less
well mineralized, but no evidence of osteophyte formation. IHC analysis
of 5 month old BMP2-Gdf5 cKO knees revealed distinct signs of pro-
gressive OA pathology including decreased expression of Col2, aggrecan
and pSmad2 and increased expression of collagen type X (ColX) and
ADAMTS5 when compared to controls.
Conclusions: BMP signaling provided by BMP2 is not required for knee
joint formation during development but is necessary for the main-
tenance of knee joint function after birth. Our ﬁndings reveal an
important role for BMP2 in the proper assembly and maturation of the
meniscus ECM that appears to be essential for joint homeostasis as mice
lacking BMP2 in Gdf5 þ cells develop spontaneous OA as they age. Our
data point to an important role for BMP2 production by cells in the knee
joint and suggest that interventions that allow for the maintenance of
adequate local BMP2 expression by these structuresmay be of beneﬁt in
the prevention of age related knee OA.
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Purpose: The mechanisms which govern osteoblast-to-osteocyte
transitions (osteocytogenesis) are yet to be established, however their
dysregulation is likely to contribute to osteoarthritic (OA) subchondral
bone sclerosis. The transmembrane glycoprotein E11 is critical in early
osteocyte commitment thus here we sought to determine the mecha-
nism regulating its expression during osteocytogenesis and to examine
whether this was compromised in OA.
Methods:We have used immunohistochemistry, RT-qPCR and western
blotting to examine the temporal and spatial localisation of E11 duringosteocytogenesis. To examine the functional role of E11 we transfected
the late osteoblast MLO-A5 cell line with E11 over-expressing and
empty vector pLVX plasmids using Fugene HD. Using these cells we
have investigated the post-translational regulation of E11, through
addition of calpain and proteasome inhibitors (Z-FA-FMK, E64d, cal-
peptin, ALLN and MG132, lactacystin, Bortezomib, Withaferin-A,
respectively) and subsequent western blotting and RT-qPCR analysis.
We have generatedmice harbouring a conditional deletion of E11 in late
osteoblasts (osteocalcin promoter driven) (OB-E11-/-) and analysed its
bone phenotype through histology, RT-qPCR and micro-CT scanning.
We have also examined the natural OA model, the STR/Ort mouse, with
regards to E11 expression.
Results: We reveal increased expression of E11 protein/mRNA
(P<0.001) concomitant with extensive osteocyte dendrite formation
and matrix mineralization (P<0.001) in MLO-A5 cell cultures. Whilst
MLO-A5 cells transfected with E11 over-expressing pLVX plasmids
exhibited signiﬁcantly increased mRNA expression (P<0.001), western-
blotting failed to detect any correlative increases in protein expression,
suggestive of post-translational regulation. We therefore treated MLO-
A5 cells with calpeptin and ALLN and found that both promoted E11
protein expression, with ALLN having the greatest effect. Treatment of
MLO-A5 cells and osteocytic IDG-SW3 cells with ALLN also induced a
profound increase in stellate cell morphology (50%, P<0.001) and
increased E11 protein expression, whilst calpeptin treatment failed to
promote similar osteocytogenic changes. Alternative calpain inhibitors
E64d and Z-FA-FMK also failed to modify MLO-A5 cell morphology or
E11 protein expression. Unchanging calpain 1/2 levels upon osteocytic
differentiation during 15-day MLO-A5 time course suggests lack of
calpain contribution to osteocytogenesis. Due to the dual roles for ALLN
in calpain and proteasome inhibition, this characterized proteasomal
degradation as the key pathway in E11 post-translational targeting and
degradation. This was supported by studies using the proteasome
inhibitors MG132, lactacystin, Bortezomib and Withaferin-A which
produced similar dose-dependent increases in E11 expression in MLO-
A5 cells. These data implicate proteasome degradation in controlling
E11 stability. Preliminary microCT analyses of OB-E11-/- mice revealed
decreased trabecular bone volume/tissue volume (27%) associated with
decreased trabecular number (16%) and thickness (7%) in comparison to
control mice. This pilot data has also revealed that the conditional
deletion of E11 in osteoblasts results in decreased cortical cross-sec-
tional thickness (12%). Further analyses will enable a more thorough
skeletal phenotyping of these mice which will include osteocyte
number and dendrite formation. Examination of a natural model of OA,
the STR/Ort mouse, revealed decreased E11 protein expression in the
subchondral bone osteocytes in regions of the joint where OA pathology
is observed.
Conclusions: Together these data suggest that proteasome-mediated
E11 protein degradation limits acquisition of the osteocyte phenotype
and that its deregulation may contribute to bone changes observed in
OA.
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Purpose: Femoroacetabular impingement (FAI) is a cause of pain and
osteoarthritis. The pathogenesis of this condition remains poorly
understood and this limits the ability to develop treatment strategies.
Cam morphology is thought to develop during adolescence, often in
association with intense sporting activity. Postulated mechanisms
include a subclinical slipped upper femoral epiphysis (SUFE) or
extension of the epiphysis along the anterosuperior femoral neck. Cam
morphology has an extremely high prevalence amongst professional
footballers making them an ideal cohort to study disease
pathogenesis.
Methods: Players at an English Premiership Football (Soccer) Club
Academy were invited to participate using a randomisation algorithm
within each age group. The cross-sectional cohort was loaded towards
the youngest age groups to enhance a future longitudinal study. 20
players were selected from the U10 and U11 teams, and 10 players
from the U12, U13, U14, U15, U16, and U18 teams (n¼100).
